BRASILIA (Reuters) – The CoronaVac COVID-19 vaccine developed by China’s Sinovac Biotech has a general efficacy of less than 60% in its clinical trial in Brazil, the news portal UOL reported on Monday, citing two sources that had seen the results.
Sao Paulo’s Butantan biomedical center, which has partnered with Sinovac to produce the vaccine in Brazil, plans to release general efficacy results on Tuesday as it seeks emergency use for the shot from health regulator Anvisa. It called the report “purely speculative.”
(Reporting by Anthony Boadle; Editing by Leslie Adler)
